Edition:
United States

Eli Lilly and Co (LLY)

LLY on New York Consolidated

83.89USD
23 Jun 2017
Change (% chg)

$-0.42 (-0.50%)
Prev Close
$84.31
Open
$84.12
Day's High
$84.34
Day's Low
$83.71
Volume
3,928,031
Avg. Vol
3,874,763
52-wk High
$86.72
52-wk Low
$64.18

Latest Key Developments (Source: Significant Developments)

Eli Lilly files supplemental biologics license application with FDA for Taltz
Thursday, 15 Jun 2017 10:35am EDT 

June 15 (Reuters) - Eli Lilly And Co :Eular 2017: Lilly's Taltz (ixekizumab) demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate response or intolerance to TNF inhibitors.Eli Lilly and Co - Lilly has filed a supplemental biologics license application with FDA for Taltz as a treatment of adult patients with active PSA.Eli Lilly - patients treated with either dosing regimen of Taltz experienced significant improvements compared with placebo in other key secondary measures.Eli Lilly and Co - submissions to other regulatory agencies around world are expected later in the year for Taltz.Eli Lilly and Co- serious adverse events and discontinuation rates due to adverse events were not significantly different between treatment groups.Incidence of treatment-emergent adverse events was greater with Taltz treatment compared with placebo.Taltz is also in Phase 3 trials for treatment of radiographic and non-radiographic axial spondyloarthritis.  Full Article

Lilly says Jardiance tablets to be studied in chronic kidney disease
Monday, 12 Jun 2017 08:00am EDT 

June 12 (Reuters) - Eli Lilly And Co ::Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease.Says plans to conduct a new, large clinical outcomes trial investigating Jardiance along with Boehringer Ingelheim.Eli Lilly And Co - ‍trial will enroll people with chronic kidney disease both with and without type 2 diabetes​.Says trial will enroll people with chronic kidney disease both with and without type 2 diabetes.Eli Lilly - ‍boehringer Ingelheim, co announced plans to conduct new, large clinical outcomes trial investigating Jardiance tablets.  Full Article

Lilly announces strategic collaboration with Keybioscience
Thursday, 8 Jun 2017 06:30am EDT 

June 8 (Reuters) - Eli Lilly And Co :Lilly announces strategic collaboration with Keybioscience AG.Eli Lilly and Co - under terms of agreement, Lilly will receive worldwide rights to develop and commercialize these molecules.Eli Lilly and Co - ‍under terms of agreement, Lilly will receive worldwide rights to develop and commercialize these molecules​.Says collaboration includes access to Dacra platform with multiple molecules including KBP-042, KBP-089 and KBP-056.Eli Lilly and Co - there will be no change to company's FY non-GAAP earnings per share guidance as a result of this transaction.Says Keybioscience has initiated phase 2 development with KBP-042.Eli Lilly and Co - expects to incur an acquired in-process research and development charge to earnings in 2017 of approximately $0.03 per share.To incur an acquired in-process research and development charge to earnings in 2017 of approximately $0.03 per share..In exchange for these rights, Keybioscience will receive an initial payment of $55 million.Eli Lilly and Co - co, Keybioscience AG have agreed to a new collaboration focused on development of dual Amylin Calcitonin receptor agonists​.  Full Article

Eli Lilly says Derica Rice to retire as CFO
Thursday, 1 Jun 2017 06:45am EDT 

June 1 (Reuters) - Eli Lilly And Co ::Derica Rice to retire as Lilly chief financial officer.Derica Rice to retire as Lilly chief financial officer.Says is considering internal and external candidates to succeed Rice.Says Rice will continue in position through 2017, successor named at a later date.  Full Article

Eli Lilly announces phase 3 RANGE Urothelial cancer trial of CYRAMZA met primary endpoint
Wednesday, 31 May 2017 06:45am EDT 

May 31 (Reuters) - Eli Lilly and Co ::Lilly announces phase 3 RANGE Urothelial cancer trial of cyramza® (ramucirumab) met primary endpoint, improving progression-free survival.Eli Lilly and Co - ‍trial met primary endpoint​.Says it anticipates that overall survival results are likely to be required for global regulatory submissions.Eli Lilly and Co - although primary endpoint has been met, Lilly anticipates overall survival results are likely to be required for global regulatory submissions.Says final OS results are currently expected in mid-2018.  Full Article

United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company
Thursday, 18 May 2017 06:07am EDT 

May 18 (Reuters) - United Therapeutics Corp :United Therapeutics Corp - on May 17, 2017, co entered into first amendment to license agreement with Eli Lilly and company.United therapeutics - amendment to clarify and extend term of agreement and to amend economic terms of agreement following a patent expiry in nov 2017.  Full Article

3Sbio Inc enters distribution and promotion agreement with two subsidiaries of Eli Lilly
Tuesday, 16 May 2017 07:56am EDT 

May 16 (Reuters) - 3sbio Inc <1530.HK>:Enters distribution and promotion agreement with two subsidiaries of Eli Lilly and co for distribution and promotion of insulin products.Co has been granted exclusive right of distribution and promotion of Humulin, an insulin product of Lilly, in China from July 1, 2017.3Sbio will establish a marketing and promotion team which will cover a wide array of diabetes products, including Humulin.  Full Article

Lupin and Lilly expand partnership in India
Tuesday, 16 May 2017 06:22am EDT 

May 16 (Reuters) - Lupin Ltd :Says Lupin and Lilly expand partnership in India.Says Lilly will be responsible for manufacturing and importing the product.Says exclusive licensing agreement with Eli Lilly enables lupin to commercialize and distribute cialis.  Full Article

Soros Fund Management dissolves share stake in Ebay Inc
Monday, 15 May 2017 05:45pm EDT 

May 15 (Reuters) - Soros Fund Management ::Soros Fund Management dissolves share stake in eBay Inc.Soros Fund Management takes share stake of 3,900 shares in Eli Lilly & Co.Change in holdings are as of march 31, 2017 and compared with the previous quarter ended as of dec 31, 2016.  Full Article

Lilly announces positive results for three phase 3 studies of galcanezumab
Friday, 12 May 2017 06:45am EDT 

May 12 (Reuters) - Eli Lilly And Co : :Lilly announces positive results for three phase 3 studies of galcanezumab for the prevention of episodic and chronic migraine.Eli Lilly and Co - galcanezumab, an investigational treatment for prevention of episodic and chronic migraine, met its primary endpoint.Eli Lilly and Co - galcanezumab primary endpoint in three phase 3 studies (evolve-1, evolve-2 and regain).Eli Lilly and Co - also is evaluating galcanezumab for treatment of cluster headache, with phase 3 trial results expected in 2018.Eli Lilly and Co - patients treated with galcanezumab experienced statistically significant improvement versus placebo on several pre-specified secondary endpoints.Says it will submit a biologics license application to u.s. Food and drug administration (FDA) for galcanezumab in second half of 2017.Eli Lilly and Co - based on unmet medical need and significance of this disease for patients, lilly has been granted fast track designation from FDA.Says the BLA submission will be followed by submissions to other regulatory agencies around world.Eli Lilly and Co- in the three studies, most commonly-reported adverse events were injection site reactions, including pain.  Full Article

More From Around the Web

BRIEF-Eli Lilly and Co sets quarterly dividend of $0.52 per share

* Sets quarterly dividend of $0.52per share Source text for Eikon: Further company coverage: